Grifols SA (GRLS.MC)

GRLS.MC on Madrid SE C.A.T.S.

29.46EUR
11:35am EDT
Price Change (% chg)

€0.13 (+0.44%)
Prev Close
€29.33
Open
€29.39
Day's High
€29.53
Day's Low
€28.86
Volume
683,136
Avg. Vol
641,969
52-wk High
€32.04
52-wk Low
€20.06

GRLS.MC

Chart for GRLS.MC

About

Grifols SA is a Spain-based company engaged in the healthcare sector. The Company is involved in the research, development, manufacturing and marketing of medical solutions for hospitals, which include plasma-derived therapies, as well as diagnosis and pharmaceutical products. Its activities are structured in four segments:... (more)

Overall

Beta: 0.45
Market Cap (Mil.): €9,178.46
Shares Outstanding (Mil.): 343.78
Dividend: 0.20
Yield (%): 0.68

Financials

  GRLS.MC Industry Sector
P/E (TTM): 35.12 32.01 32.18
EPS (TTM): 0.84 -- --
ROI: 5.52 19.61 18.91
ROE: 15.40 20.45 19.87
Search Stocks

Latest News about GRLS.MC

Grifols signs deal to license Aradigm's Pulmaquin

MADRID, May 21 - Spanish drugmaker Grifols said on Tuesday it has signed an exclusive contract to license U.S. Aradigm Corporation's Pulmaquin compound and may take a stake in the California-based firm.

21 May 2013

Spain's Grifols says Q1 net profit up 19 pct y/y

MADRID, May 2 - Spanish pharmaceutical company Grifols said on Thursday net profit rose 19 percent in the first quarter of 2013 from a year earlier to 115.7 million euros ($152.6 million), boosted by overseas sales, especially Latin America and Asia.

02 May 2013

Spain's Grifols reports fivefold increase in 2012 profit

MADRID, Feb 28 - Spanish pharmaceutical company Grifols reported a more than fivefold rise in full-year profit for 2012 to 257 million euros ($336.90 million), buoyed by its acquisition of U.S. firm Talecris last June and its wide geographic presence outside its depressed home market.

28 Feb 2013
» More GRLS.MC News

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
GRIFOLS SA (GRFS) - REPORT FOR ACTIVE TRADERS
Provider: Pechala's Reports
$25.00
Buy
Grifols - Finlabo Research Equity Report: Fundamental and Technical Analysis and 6 months performance forecast
Provider: Finlabo SIM Spa
$10.00
Buy
Grifols SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
$20.00
Buy
GRIFOLS SA (GRFS) 12-months forecast
Provider: Pechala's Reports
$15.00
Buy
ValuEngine Detailed Valuation Report for GRFS
Provider: ValuEngine, Inc.
$127.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research
Search Stocks